Oyster Point Pharma, Inc. announced the expansion of patient access to TYRVAYA® (varenicline solution) Nasal Spray and provided an update on the commercial performance of TYRVAYA in the U.S. The Company continues to expand access to TYRVAYA for patients with dry eye disease. As of July 2022, TYRVAYA is now covered by commercial prescription drug plans managed by the nation's top three Pharmacy Benefit Manager Group Purchasing Organizations. The Company has also introduced in July expanded patient access programs to include more eligible patients.

Looking forward, the Company continues to expect to further expand access to TYRVAYA with coverage for Medicare Part D patients in 2023, and as early as the fourth quarter of 2022. The expansion of patient access to TYRVAYA comes as the Company continues to build upon its launch success. Launch to date as of July 1, 2022, TYRVAYA prescriptions have already been written by approximately 7,400 eye care prescribers (ECPs) out of the approximately 21,000 total ECPs targeted by the Company's field-based sales resources.

Based on third-party data, among ECPs who have written a commercial TYRVAYA prescription, TYRVAYA has reached approximately 21% market share1 of commercial new-to-brand prescriptions (NBRx) as of the week ending July 1, 2022, driven by strong utilization among ECPs. Notably, this result was achieved in just eight months since the launch of TYRVAYA in the U.S.